TY - JOUR T1 - Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines JF - Anticancer Research JO - Anticancer Res SP - 3821 LP - 3828 VL - 35 IS - 7 AU - KATSUHISA HIRANO AU - TOMOYUKI OKUMURA AU - YUTAKA SHIMADA AU - TORU WATANABE AU - TETSUJI YAMAGUCHI AU - TAKUYA NAGATA AU - KAZUHIRO TSUKADA Y1 - 2015/07/01 UR - http://ar.iiarjournals.org/content/35/7/3821.abstract N2 - Background: Pancreatic carcinoma (PC) is among the most lethal types of carcinomas worldwide. We aimed to establish well-defined PC cell lines in order to determine their resistance to chemotherapy. Materials and Methods: Cells cultured from the tumors of two patients were analyzed for xenograft formation, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and TP53 mutations, chemosensitivity, and mRNAs encoding rate-limiting enzymes that metabolize anticancer drugs. Results: The TYPK-1 and TYPK-2 cell lines were established from the lymph node of a locally advanced PC and from the ascites of a multi-metastatic and multi-chemoresistant PC, respectively. Each cell line generated tumors in nude mice. KRAS and TP53 mutations were detected in TYPK-1 but not TYPK-2 cells. TYPK-1 cells were resistant to gemcitabine, and TYPK-2 cells were resistant to oxaliplatin. The gemcitabine sensitivity of each cell line correlated with the expression of mRNAs encoding DCK and SLCAC29A1. Conclusion: TYPK-1 and TYPK-2 cells may contribute to investigations of resistance to anticancer drugs. ER -